Ixazomib: Phase II data

Data from 21 evaluable newly diagnosed MM patients who responded to induction therapy with ixazomib, Revlimid lenalidomide and dexamethasone in an open-label Phase II trial showed that maintenance treatment with oral ixazomib alone led to a VGPR or better, the primary endpoint defined as complete response or VGPR, in 15 (71%) patients. Of those patients, 11 had a complete response or better. Median progression-free survival (PFS) has not yet been reached. Median time to first response, defined as a partial response or better, was 0.99 months and median time to best response was 7.46 months. During the maintenance period, there were no discontinuations due to adverse events or on-study deaths. Treatment-related grade 3 adverse events included 1 case each of hypokalemia, thrombocytopenia and cataract as reported by the investigator. ...